Clients and investigator sites benefit from improved processes and better data access
WILMINGTON, N.C. (February 10, 2016) – Pharmaceutical Product Development, LLC (PPD) is expanding Preclarus®, its award-winning clinical data platform, to include a comprehensive set of data solutions that supports the company’s central lab operations. These changes will enable study sites to access clean central lab data in real time, improve inventory management and order tracking, facilitate patient management and safety, and establish complete chain of custody for samples. The goal of these enhancements is to increase the efficiency and effectiveness of managing central lab data for PPD’s clients.
With the expansion of the Preclarus brand, PPD® Laboratories is introducing the new Preclarus investigator site portal to support clinical trial sites. This portal is a key enhancement for PPD Laboratories’ clients because it builds upon the company’s current capabilities to provide sites with new tools and options to access clinical trial data and help better manage their patients. The company’s newly named Preclarus central lab database will continue to support the company’s central lab operations and project teams with real-time, studywide lab results, project status and site metrics.
“Preclarus offers our clients an unprecedented view of central laboratory data that support their clinical trials,” explains David Johnston, Ph.D., executive vice president of PPD Laboratories. “With its real-time access to study details, patient data and laboratory results, Preclarus drives informed decision-making and increased efficiency for PPD Laboratories and its clients.”
Preclarus is PPD’s comprehensive data solution that consolidates and standardizes data from multiple sources to give PPD teams and clients transparent, real-time access to clinical trial operations and patient data, which can be visualized on interactive dashboards. Coupled with sophisticated analytics that enable innovative research approaches, Preclarus provides the transparent reporting and analytic capabilities needed to turn data into actionable intelligence.
The new central lab portal is designed to make it easier for investigational sites to support PPD clinical trials. The reports and tools within the Preclarus investigator site portal simplify every process, including adding patients to the trial, ordering sample collection kits, reviewing laboratory results, managing patients and critical values, and accessioning and shipping samples to PPD. The new portal also provides on-site biorepository tools to help clients manage samples at their site and track them to their final destinations.
PPD Laboratories combines world-class scientific expertise with state-of-the art technologies supported by a commitment to exceptional quality. From early development through late stage research, clients benefit from comprehensive lab services spanning bioanalytical, vaccine sciences, GMP, central lab testing and biomarkers.
About PPD
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 14,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development to deliver life-changing therapies that improve health.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.